Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287558 · ClinicalTrials.gov registry record · Phase 1
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
A Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Idiopathic Vascular Ectasia, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02287558 is a Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Idiopathic Vascular Ectasia that has completed, run by The Cleveland Clinic. The registered enrollment target is 9 participants, below the 1,789-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02287558, a Phase 1 study of Hereditary Hemorrhagic Telangiectasia and Idiopathic Vascular Ectasia, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate patients \> 18 years of age with transfusion-dependent gastrointestinal bleeding due to documented gastrointestinal vascular ectasia with or without concurrent hereditary hemorrhagic telangiectasia (HHT). This study will focus on documented bleeding sites in the small bowel, including the duodenum, jejunum and ileum. Eligible patients will have endoscopically-documented sites of vascular ectasia and will have required at least 4 units of blood transfusion or episodes of intravenous iron administration over the preceding four months.
Conditions Studied
Interventions
- DRUG Pomalidomide
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-01-27 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287558
The ClinicalTrials.gov registry entry for NCT02287558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,789-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which Pomalidomide is the first listed.
NCT02287558 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02287558 about?
NCT02287558 is a clinical study titled "Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study". This study will evaluate patients \> 18 years of age with transfusion-dependent gastrointestinal bleeding due to documented gastrointestinal vascular ectasia with or without concurrent hereditary hemorrhagic telangiectasia (HHT). This study will focus on documented bleeding sites in the small bowel,...
What is the current status of trial NCT02287558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-01-27. Estimated completion is 2019-06-01.
What conditions does trial NCT02287558 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia.
What interventions are being tested in trial NCT02287558?
The interventions under investigation include: Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT02287558?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02287558 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
RECRUITING · Phase 1
-
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
COMPLETED · Phase 1
-
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
RECRUITING
-
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING
-
Ultra-low-dose Chest CT for HHT
ACTIVE NOT RECRUITING
-
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.